Trial Profile
A Phase Ib Study to Assess the Safety, Tolerability and Immunologic Activity of Preoperative IRX 2 In Early Stage Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Feb 2024
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Indometacin (Primary) ; IRX 2 (Primary) ; Multivitamin (Primary) ; Omeprazole (Primary) ; Zinc (Primary)
- Indications Early breast cancer; Triple negative breast cancer
- Focus Adverse reactions
- 25 Jan 2024 Planned End Date changed from 1 Jan 2023 to 1 May 2024.
- 31 Jan 2022 Planned End Date changed from 31 Dec 2020 to 1 Jan 2023.
- 31 Jan 2022 Planned primary completion date changed from 1 Apr 2018 to 1 Oct 2022.